
Nicholas Weber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/641695/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome postâ€allogeneic transplantation. British Journal of Haematology, 2020, 188, 570-581.	2.5	37
2	Tolerability of proactive enteral nutrition post allogeneic haematopoietic progenitor cell transplant: A randomised comparison to standard care. Clinical Nutrition, 2020, 39, 1364-1370.	5.0	18
3	Nutrition support during allogeneic stem cell transplantation: evidence versus practice. Supportive Care in Cancer, 2020, 28, 5441-5447.	2.2	15
4	â€~Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 2018, 59, 1514-1516.	1.3	11
5	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. Journal of Infection and Chemotherapy, 2019, 25, 503-508.	1.7	8
6	Transient immune-mediated agranulocytosis following <i>Mycoplasma pneumoniae</i> infection. BMJ Case Reports, 2018, 2018, bcr-2018-224537.	0.5	2
7	An Individualized Exercise Intervention for People with Multiple Myeloma—Study Protocol of a Randomized Waitlist-Controlled Trial. Current Oncology, 2022, 29, 901-923.	2.2	2
8	The role of hematopoietic stem cell transplantation for relapsed and refractory <scp>H</scp> odgkin lymphoma. American Journal of Hematology, 2015, 90, E145.	4.1	1
9	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2020, 136, 4-5.	1.4	1
10	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1
11	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 2021, 138, 2728-2728.	1.4	1
12	Weekly Cyclophosphamide-Bortezomib-Dexamethasone Induction Performs Comparably to Twice-Weekly Dosing with Respect to Both Response Rates and Survival after Autologous Transplant. Acta Haematologica, 2020, 143, 295-296.	1.4	0